FSA Advisors Inc. Purchases 62 Shares of Eli Lilly and Company (NYSE:LLY)

FSA Advisors Inc. grew its position in Eli Lilly and Company (NYSE:LLY) by 12.8% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 547 shares of the company’s stock after buying an additional 62 shares during the period. FSA Advisors Inc.’s holdings in Eli Lilly and Company were worth $452,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of LLY. WestEnd Advisors LLC raised its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares during the last quarter. Citizens National Bank Trust Department raised its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $43,000. Finally, O Brien Wealth Partners LLC raised its position in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after buying an additional 12 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Morgan Stanley reaffirmed an “overweight” rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their target price for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Hsbc Global Res lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. Finally, Guggenheim lifted their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a “buy” rating in a report on Friday, July 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,012.56.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $807.78 on Tuesday. The stock has a 50 day moving average price of $773.01 and a 200 day moving average price of $800.67. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $765.57 billion, a price-to-earnings ratio of 65.73, a price-to-earnings-growth ratio of 1.18 and a beta of 0.40. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. Eli Lilly and Company’s revenue was up 45.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.58 earnings per share. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.